SG11201908056QA - Anti-par2 antibodies and uses thereof - Google Patents
Anti-par2 antibodies and uses thereofInfo
- Publication number
- SG11201908056QA SG11201908056QA SG11201908056QA SG11201908056QA SG11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA SG 11201908056Q A SG11201908056Q A SG 11201908056QA
- Authority
- SG
- Singapore
- Prior art keywords
- building
- cambridge
- milstein
- international
- granta park
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 abstract 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 abstract 2
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 abstract 2
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT omit VIII °nolo VIII ioo Ill mom OII iflo oimIE (10) International Publication Number WO 2018/167322 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/EP2018/056776 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,462 16 March 2017 (16.03.2017) US 62/637,766 02 March 2018 (02.03.2018) US (71) Applicant: MEDIMMUNE LIMITED [GB/GB]; Mil- stein Building Granta Park, Cambridge CB21 6GH (GB). (72) Inventors: DOBSON, Claire; Milstein Building Granta Park, Cambridge CB21 6GH (GB). WILLIAMS, Richard; Milstein Building Granta Park, Cambridge CB21 6GH (GB). GURRELL, Ian; Milstein Building Granta Park, Cambridge CB21 6GH (GB). PODICHETTY, Sadhana; Milstein Building Granta Park, Cambridge CB21 6GH (GB). FAIRMAN, David; Milstein Building Granta Park, Cambridge CB21 6GH (GB). THORNTON, Peter; Mil- stein Building Granta Park, Cambridge CB21 6GH (GB). NEWTON, Philip; Milstein Building Granta Park, Cam- bridge CB21 6GH (GB). (74) Agent: RASHID, Jeremy et al.; 5 Old Broad Street, Lon- don EC2N 1DW (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, N 00 (54) Title: ANTI-PAR2 ANTIBODIES AND USES THEREOF 0 (57) : The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodi- \" ments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further 0 provides methods for making and using the antibodies and antigen-binding fragments.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 | |
| PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908056QA true SG11201908056QA (en) | 2019-09-27 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908056QA SG11201908056QA (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10836822B2 (en) |
| EP (1) | EP3596125A1 (en) |
| JP (2) | JP7222901B2 (en) |
| KR (1) | KR20190129925A (en) |
| CN (1) | CN110446720B (en) |
| AU (2) | AU2018235031B2 (en) |
| BR (1) | BR112019018752A2 (en) |
| CA (1) | CA3055251A1 (en) |
| CL (1) | CL2019002626A1 (en) |
| CO (1) | CO2019010975A2 (en) |
| CR (1) | CR20190417A (en) |
| IL (1) | IL269134B1 (en) |
| MA (1) | MA49886A (en) |
| MX (1) | MX2019010802A (en) |
| NZ (1) | NZ757915A (en) |
| PH (1) | PH12019502087A1 (en) |
| SG (1) | SG11201908056QA (en) |
| TW (1) | TWI788332B (en) |
| UA (1) | UA125757C2 (en) |
| WO (1) | WO2018167322A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102056946A (en) | 2008-04-11 | 2011-05-11 | 中外制药株式会社 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| KR102568454B1 (en) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| PT3233921T (en) | 2014-12-19 | 2021-12-09 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| TWI779010B (en) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE |
| MX2017008978A (en) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof. |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| EP4200018A1 (en) * | 2020-08-18 | 2023-06-28 | Cephalon LLC | Anti-par-2 antibodies and methods of use thereof |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2004080373A2 (en) * | 2003-03-11 | 2004-09-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| JP5848861B2 (en) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Human monoclonal antibody against CD20 |
| WO2006052723A2 (en) * | 2004-11-04 | 2006-05-18 | New England Medical Center Hospitals, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (en) * | 2007-06-29 | 2008-10-03 | Amgen Inc | PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM. |
| AR070911A1 (en) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | USE OF PARTA RECEPTOR ANTAGONISTS ACTIVATED WITH PROTEASA |
| CN102056946A (en) | 2008-04-11 | 2011-05-11 | 中外制药株式会社 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| MX2010011717A (en) | 2008-05-01 | 2010-11-30 | Amgen Inc | Anti-hepcidin antibodies and methods of use. |
| US20100119506A1 (en) | 2008-08-05 | 2010-05-13 | Boehringer Ingelheim International Gmbh | Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation |
| JO3246B1 (en) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | High affinity human antibodies to human protease-activated receptor-2 |
| BR112012022917A2 (en) | 2010-03-11 | 2017-01-10 | Pfizer | ph-dependent antigen binding antibodies |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| EA028244B1 (en) | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS |
| CA2953714C (en) * | 2014-06-30 | 2021-05-18 | Ralf Guenther | Anti-tnfa antibodies with ph-dependent antigen binding |
-
2018
- 2018-03-16 UA UAA201910275A patent/UA125757C2/en unknown
- 2018-03-16 MA MA049886A patent/MA49886A/en unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/en unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 KR KR1020197030092A patent/KR20190129925A/en not_active Application Discontinuation
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/en active Active
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en unknown
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/en active Active
- 2018-03-16 TW TW107109179A patent/TWI788332B/en active
- 2018-03-16 IL IL269134A patent/IL269134B1/en unknown
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
- 2018-03-16 BR BR112019018752A patent/BR112019018752A2/en unknown
- 2018-03-16 CR CR20190417A patent/CR20190417A/en unknown
- 2018-03-16 EP EP18714185.8A patent/EP3596125A1/en active Pending
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
-
2019
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/en unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983A1/en active Pending
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/en active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7222901B2 (en) | 2023-02-15 |
| CN110446720A (en) | 2019-11-12 |
| TWI788332B (en) | 2023-01-01 |
| AU2021257983A1 (en) | 2021-11-25 |
| AU2018235031B2 (en) | 2021-08-12 |
| CA3055251A1 (en) | 2018-09-20 |
| NZ757915A (en) | 2023-05-26 |
| CL2019002626A1 (en) | 2019-12-06 |
| KR20190129925A (en) | 2019-11-20 |
| CR20190417A (en) | 2019-12-06 |
| PH12019502087A1 (en) | 2020-03-09 |
| US20210061905A1 (en) | 2021-03-04 |
| EP3596125A1 (en) | 2020-01-22 |
| BR112019018752A2 (en) | 2020-05-05 |
| TW201843176A (en) | 2018-12-16 |
| WO2018167322A1 (en) | 2018-09-20 |
| IL269134B1 (en) | 2024-03-01 |
| JP2023055895A (en) | 2023-04-18 |
| US11591389B2 (en) | 2023-02-28 |
| US20180305450A1 (en) | 2018-10-25 |
| IL269134A (en) | 2019-11-28 |
| US20230242639A1 (en) | 2023-08-03 |
| CN110446720B (en) | 2023-09-12 |
| JP2020509762A (en) | 2020-04-02 |
| UA125757C2 (en) | 2022-06-01 |
| AU2018235031A1 (en) | 2019-10-31 |
| CO2019010975A2 (en) | 2019-10-21 |
| MA49886A (en) | 2020-06-24 |
| MX2019010802A (en) | 2019-10-30 |
| US10836822B2 (en) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel |